Thus, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for glomerulonephritis recommend ACE inhibitors as first-line treatment for patients with IgA nephropathy with proteinuria of more than 1 g/day (recommendation level 1B) (34). This evidence concerns the gene ACE and IgA glomerulonephritis.